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Abstract
Malignant melanoma has increased incidence worldwide and causes most skin cancer–related deaths. A few cell surface antigens that can be
targets of antitumor immunotherapy have been characterized in melanoma. This is an expanding field because of the ineffectiveness of conven-
tional cancer therapy for the metastatic form of melanoma. In the present work, antimelanoma monoclonal antibodies (mAbs) were raised against
B16F10 cells (subclone Nex4, grown in murine serum), with novel specificities and antitumor effects in vitro and in vivo. MAb A4 (IgG2ak) recog-
nizes a surface antigen on B16F10-Nex2 cells identified as protocadherin β13. It is cytotoxic in vitro and in vivo to B16F10-Nex2 cells as well as
in vitro to human melanoma cell lines. MAb A4M (IgM) strongly reacted with nuclei of permeabilized murine tumor cells, recognizing histone 1.
Although it is not cytotoxic in vitro, similarly with mAb A4, mAb A4M significantly reduced the number of lung nodules in mice challenged intra-
venously with B16F10-Nex2 cells. The VH CDR3 peptide from mAb A4 and VL CDR1 and CDR2 from mAb A4M showed significant cytotoxic
activities in vitro, leading tumor cells to apoptosis. A cyclic peptide representing A4 CDR H3 competed with mAb A4 for binding to melanoma
cells. MAb A4M CDRs L1 and L2 in addition to the antitumor effect also inhibited angiogenesis of human umbilical vein endothelial cells in vitro.
As shown in the present work, mAbs A4 and A4M and selected CDR peptides are strong candidates to be developed as drugs for antitumor
therapy for invasive melanoma.
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Introduction
Malignant melanoma is a deadly cancer of increasing incidence [1].
It is a heterogeneous solid tumor to which conventional therapy (e.g.,
chemotherapy and radiotherapy) is generally ineffective in its meta-
static form [2]. New advances in the understanding of melanoma’s
microenvironment and the complexity of tumor development and
immune response suggest that treatment of this disease may require
a combination of procedures. Numerous studies have tested a vari-
ety of immunotherapeutic strategies in the treatment of advanced
melanoma, including antitumor vaccines, interferon α, interleukin 2
(IL-2), dendritic cells, monoclonal antibodies (mAbs), and gene ther-
apy [3–7].
The use of mAbs in cancer treatment has increased in the past few
years. Originally, murine mAbs performed poorly in the clinic be-
cause of their short half-life and immunogenicity in the human host.
Chimeric and humanized mAbs have overcome these disadvantages.
MAbs are mostly active against membrane-bound target antigens.
They can mediate signaling by cross-linking surface antigen that leads
to cell death and may alter the cytokine milieu or enhance an active
antitumor immune response [8–10]. They may block growth factor
receptors, efficiently arresting proliferation of tumor cells [11]. Indi-
rect effects include recruiting cells that exert antitumor antibody
(Ab)-dependent cytotoxicity (ADCC), such as natural killer cells
and macrophages [12]. MAbs can also bind complement, leading
to complement-dependent cytotoxicity (CDC) [12,13]. The adverse
effects associated with mAbs depend in part on the distribution of
antigenic targets in normal tissues in addition to the intrinsic cyto-
toxicity of certain Abs. A further use of mAbs is to carry a toxin,
cytotoxic agent, or radioisotope, specifically addressing it to the tu-
mor’s growing site [14,15]. MAbs can also act to modify the tumor
microenvironment by inhibiting angiogenesis and by targeting integ-
rins [16–18]. Several Abs are currently in preclinical and clinical trials
to treat malignancies such as renal carcinoma, lymphomas, leukemia,
breast, head and neck, ovarian, pancreatic, prostate, non–small cell
lung, and colorectal cancers [19]. Molecular targets have been human
epidermal growth factor receptors (HERs; epidermal growth factor re-
ceptor, [EGFR], and HER2), cMETreceptor, insulin-like growth factor
1 receptor (IGF-1R), vascular endothelial growth factor (VEGF) and re-
ceptor (VEGFR) agents, and integrinsα5β1 andαvβ3. Aside frommAbs,
a number of small-molecule inhibitors have also been tested in clinical
and preclinical trials some already approved by the US Food and Drug
Administration [20].
In melanoma, a restricted number of mAbs have been described
with some success in tumor regression in clinical trials but with toxic
adverse effects. In vitro studies have shown that mAb R24, a mouse
immunoglobulin G (IgG) that recognizes the ganglioside GD3 [21],
had specific antimelanoma properties. R24 binding to GD3 medi-
ated ADCC as well as CDC, and infusion of R24 in patients with
metastatic melanoma showed remarkable tumor regression in some
of them [22]. Unfortunately, dose-dependent adverse effects restricted
further use of mAb R24 [23]. To overcome the immunological toler-
ance to melanoma, a human anti-CTLA4 mAb, ipilimumab, is being
tested as monotherapy and in combination with vaccines, IL-2, and
dacarbazine. Overall response rates ranged from 13% to 22% in pa-
tients with stage IV metastatic disease [24]. Preclinical studies with a
fully human Ab against melanoma cell adhesion molecule (MCAM/
MUC18) have also shown promising results [25–27]. This Ab
(ABX-MA1) had no effect on melanoma cell proliferation in vitro.
However, it significantly inhibited tumor growth of metastatic mela-
noma cell lines injected subcutaneously in nude mice. ABX-MA1
treatment also suppressed lung metastasis of these melanoma cells
[27]. MAbs represent, therefore, another modality to treat melanoma
either alone or in combination with conventional chemotherapy or
other antitumor agents.
Another approach in the immunotherapy of cancer patients in-
volves peptides [28]. Peptides can be derived from tumor-associated
antigens and be used to enhance the host immune response through
interactions with and activation of T cells [29,30]. Further improve-
ment of peptide vaccination, including the use of adjuvants, peptide-
pulsed dendritic cells, multipeptide vaccination, addition of helper
peptides, and peptide expression through the use of mini genes have
made progress in the past few years [28,30–32]. Peptides can be syn-
thesized with posttranslational modifications or protease-resistant pep-
tide bonds to increase their stability in vivo [33]. Apart from immune
peptides, there also are reports on the direct binding of peptides to
tumor cells causing inhibition of tumor growth and killing cells by
apoptosis. Antimicrobial peptides only in a few cases display antitumor
activity [34]. Nevertheless, we showed that gomesin was cytotoxic
to B16F10-Nex2 cells and human tumor cells in vitro. Topical treat-
ment with gomesin of subcutaneously grafted melanoma in mice sig-
nificantly reduced tumor growth [35].
Polonelli et al. [36] introduced the concept that short synthetic peptides
corresponding to the sequences of immunoglobulin complementarity-
determining regions (CDRs) may display antimicrobial, antiviral and
antitumor activities regardless of the Ab specificity for a particular anti-
gen. The high frequency of bioactive peptides based on CDRs suggests
that Ig molecules could be sources of unlimited number of sequences
potentially active against infectious agents and tumor cells.
Previously, we have shown that a murine mAb (A4) raised against
B16F10 tumor cells was cytotoxic in vitro in a complement-mediated
reaction and effectively thwarted tumor development in syngeneic
mice [37]. A second antimelanoma mAb (A4M) was characterized,
and in the present work, we describe their targets on tumor cells.
Both mAbs significantly inhibited lung metastases, although only
mAb A4 induced apoptosis of tumor cells in vitro. CDR peptides
derived from both Abs also showed cytotoxicity against tumor cells.
VH CDR3–derived cyclic peptides from both mAbs showed charac-
teristics of micro-Abs, including antitumor apoptotic activity in the
case of mAb A4 H3.
Materials and Methods
Cell Lines and Reagents
The following cell lines were used in the present work: B16F10-Nex2,
a subclone of B16F10 cell line originally obtained from the Ludwig
Institute for Cancer Research, São Paulo branch; human melanoma
cell lines (SKmel25, SKmel28, and Mel85); human umbilical vein
endothelial cell line (HUVEC); human promyelocytic leukemia cell
line (HL-60) and its transgenic mutants (Bcr-Abl, Bcl-2, and Bcl-XL);
hybridoma A4, raised against B16F10-Nex4 cells (in vitro cultured in
murine serum-supplemented medium) as previously described [38];
and hybridoma A4M, isolated by subcloning A4 hybridoma. All cell
lines and hybridomasweremaintained in culture inRPMI 1640medium
pH 7.2, supplemented with 10% heat-inactivated fetal bovine serum,
10 mM HEPES (N -2-hydroxyethylpiperazine-N -2-ethanesulphonic
acid), and 24 mM NaHCO3, all from Gibco (Minneapolis, MN),
and with 40 mg/L gentamicin sulfate (Hipolabor Farmacêutica, Belo
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Horizonte, Brazil). Murine anti–pan-histone Abs were purchased from
Boehringer Mannheim (Mannheim, Germany).
Monoclonal Antibodies and CDR-Based Synthetic Peptides
Hybridomas A4 and A4M were inoculated in pristane-inflamed
peritoneum of nude female mice, and mAbs-containing ascites were
collected. MAb A4 was purified as previously described [37], and
mAb A4M was purified on Sephacryl S200 (Pharmacia LKB, Uppsala,
Sweden) as described by Bouvet et al. [38]. Peptides based on CDR
sequences of mAb A4 and mAb A4M were synthesized by the solid-
phase and classic solution methods of peptide synthesis [39]. All the ob-
tained peptides were purified by semipreparative HPLC on an Econosil
C-18 column. The molecular mass and purity of synthesized peptides
(≥94%) were checked by matrix-assisted laser desorption/ionization
(MALDI)-time-of-flight (TOF) mass spectrometry, using TofSpec-E
(Micromass, Manchester, UK). Irrelevant IgG 2a (17D) and IgM
(1G6) mAbs, both raised against fungal (Paracoccidioides) antigens,
were used as isotype controls.
Western Blot Analysis
B16F10-Nex2 total lysate (1 × 107 cells) was separated in 10% SDS–
polyacrylamide gel electrophoresis and transferred to Immobilon P
transfer membrane (Millipore, Billerica, MA). The membranes were
washed in phosphate-buffered saline (PBS), pH 7.2, with Tween-20
(0.02%; PBS-T), and were blocked with 5% skimmed milk (Molico;
Nestle, São Paulo, Brazil) in PBS-T overnight (ON) at 4°C. The blots
were then probed ON at 4°C with mAb A4, A4M, or anti–pan-histone
Abs. After 1 hour of incubation with anti-IgG or anti-IgM secondary Ab
(1:2000) followed by 1 hour incubation with streptavidin-peroxidase,
immunoreactive proteins were detected by chemiluminescent ELISA
(CL-ELISA) according to the manufacturer’s instructions (ECL detec-
tion system; Amersham Biosciences, Pittsburgh, PA). B16F10 nuclear
extraction and histone detection byWestern blot analysis were followed
as previously described [35].
Immunoprecipitation
B16F10-Nex2 cells (1 × 108) were washed twice in PBS and lysed
using lysis buffer (0.9% NaCl [Merck, Whitehouse Station, NJ],
0.01 M Tris-HCl [Gibco], pH 7.2, 0.01 M MgCl2 [Merck], 0.2 M
PMSF [Gibco], and 0.5%NP-40 [LKB-Produkter, Bromma, Sweden]).
Total cell lysate (500 μg of protein) was incubated with 100 μg/ml
of mAb A4 at 4°C ON on an orbital shaker. Protein A-Sepharose
(Amersham Biosciences) was added (500 μl) to the sample and incu-
bated at 4°C ON with shaking. Sample was collected by centrifuga-
tion at 3000 rpm for 5 minutes at 4°C and washed twice with PBS-T
and once with PBS. Proteins were dissolved in SDS gel loading buffer
and subjected to 10% SDS-PAGE.
Protein Identification by Liquid Chromatography–Tandem
Mass Spectrometry
Immunoprecipitated sample was digested with trypsin as described
by Stone and Williams [40]. Briefly, the samples were dissolved in
40 μl of 400 mM NH4HCO3 containing 8 M urea, and the disulfide
bonds were reduced with 5 mM dithiothreitol for 15 minutes at
50°C. Cysteine residues were then alkylated with 10 mM iodoaceta-
mide for 15 minutes at room temperature (RT). The reaction was
diluted eight-fold, and 4 μg of trypsin (sequencing grade; Promega,
Madison, WI) was added and incubated ON at 37°C. The digestion
was terminated with 1 μl of formic acid (FA), submitted to desalting
using POROS R2 ziptips, as described elsewhere, and dried in a
speed vac (Vacufuge; Eppendorf, Westbury, NY) [41].
Samples were redissolved in 20 μl of 0.1% FA, and 8 μl was loaded
on a C18 trap column (0.25 μl; OptiPak, Oregon City, OR) coupled
to a nano-HPLC system (1D-plus; Eksigent, Dublin, CA). After wash-
ing for 10 minutes with 2% acetonitrile (ACN)/0.1% FA in a flow rate
of 5 μl/min, peptides were separated in a capillary reverse phase column
(15 cm × 75 μm, 3-μm spheres; ProteoPep 2 [NewObjective,Woburn,
MA]). A gradient was set with 5% to 40% solvent B for 100 minutes
(solvent A: 2%ACN/0.1%FA; solvent B: 80%ACN/0.1%FA) in a flow
rate of 300 nl/min. Peptides eluted were analyzed online in a linear trap
mass spectrometer (LTQXLwith ETD; Thermo Fisher Scientific, San
Jose, CA). The 10 most abundant peaks were submitted to collision-
induced dissociation (35% normalized collision energy) twice before
being dynamically excluded for 2 minutes.
The MS/MS spectra of peptides from 600 to 4000 Da were con-
verted toDTA using Bioworks (version 3.3.1; Thermo Fisher Scientific)
with a threshold of 100 counts and 15 fragments. The spectra were
searched against a database assembledwith themouse IPI (v3.25, down-
loaded on January 17, 2007, from http://www.ebi.ac.uk/IPI/IPImouse.
html) and common contaminants (trypsin and keratin, downloaded
on May 30, 2007, from http://www.ncbi.nlm.nih.gov/sites/entrez?db=
Protein&itool=toolbar) sequences, using Sequest, (Thermo, Finnigan,
San Jose, CA) [42]. All the sequences were set in the correct and inverse
orientation forming, a database with a total of 104,850 sequences. The
parameters of the database search were 2 Da for peptide mass tolerance,
cysteine carbamidomethylation (fixed modification), methionine oxida-
tion (variable modification), and a maximum of one missed cleaved site
for trypsin digestion. The false-positive rate was calculated to be 1.2% to
2.9% depending on the data set after applying the following filters:
DCn > 0.1; Xcorr > 1.5, 2.2, 2.7 for singly, doubly, and triply charged
peptides, respectively; distinct peptides; and a protein probability < 1e−3.
Confocal Microscopy
B16F10-Nex2 cells (2 × 103) were cultivated on round glass cover-
slips (13 mm) for 24 hours after fixation with 3.7% formaldehyde for
15 minutes at RT. Cells were then incubated with block solution
(150 mM NaCl [Merck], 50 mM Tris [Invitrogen, Carlsbad, CA],
0.25% bovine serum albumin [BSA; Sigma, St Louis, MO], and
0.5% Tween-20 [Sigma], pH 7.2) for 1 hour at RT. A4M or anti–
pan-histone Abs (5 mg/ml) were incubated for 12 hours at 4°C. After
several washes in PBS, biotinylated antimouse IgM or antimouse IgG
(1:500; Sigma) were incubated at RT for 1 hour after incubating with
streptavidin–fluorescein isothiocyanate (FITC; 1:250; BD Biosciences,
San Jose, CA). Alternatively, antimouse IgG rhodamine conjugate
(1:250) was used to colocalize histones in the tumor cells. Staining of
actin filaments and nuclei was performed with 0.3 μg/ml phalloidin-
rhodamine conjugate (Invitrogen) and 50 μg/ml 4′6-diamidino-2-
phenylindole, dihydrochloride (DAPI; Invitrogen), respectively, for 1 hour
at RT. To remove histones from tumor cells, coverslips coated with
B16F10 cells were previously treated with 0.4N sulfuric acid for 30 min-
utes on ice. After several washes in PBS, the reaction was carried out as
described above. The coverslips were treated with a mounting medium
(Vectashield; Vector Laboratories, Burlingame, CA) to reduce bleaching
and were examined by laser scanning fluorescence confocal microscope
(MRC 1024/UV System; Bio-Rad, Hercules, CA) equipped with a
transmitted light detector for Nomarski differential interference contrast.
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The images were obtained with a 40× 1.2NA/water immersion PlanApo
objective (Carl Zeiss MicroImaging, Inc, Thornwood, NY); Kalman
averaging at least 20 frames using a 2-mm iris (pinhole).
In Vitro Cytotoxicity Analysis
MAbs or CDR peptides (linear or cyclic) were diluted in supple-
mented RPMI medium at different concentrations and incubated
with 5 × 103 B16F10-Nex2 or human tumor cells in 96-well plates;
cells were plated 24 hours before treatment. After ON incubation at
37°C, viable cells were counted in a Neubauer chamber (Electron
Microscopy Sciences, Hatfield, PA) using Trypan blue. Alternatively,
cell proliferation was measured using the Cell Proliferation Kit I
(MTT; Boehringer Mannheim), an MTT-based colorimetric assay
for quantification of cell proliferation and viability. Readings were
made in an ELISA plate reader at 570 nm. Values are indicated as
mean percentage variation of cell death and normalized to control.
Each assay was performed in triplicate. Similar results were obtained
in at least three independent experiments.
DNA Fragmentation Assay
B16F10-Nex2 cells as well as humanmelanoma cell lines were grown
for 24 hours in 12-well plates (105 cells/well) and were then further
incubated for 12 hours at 37°C with either the mAb A4 (100 μg/ml)
or the synthetic CDR peptides (0.1 mM of A4 H3, 0.8 mM of A4M
L1, and 0.6 mM of A4M L2). The DNA extraction and fragmenta-
tion analyses were carried out as previously described [36].
Apoptosis/Necrosis Detection
B16F10-Nex2 cells were grown for 24 hours in a six-well plate (5 ×
105 cells/well) and further incubated with mAb A4 (100 μg/ml) for
6 and 12 hours at 37°C. For negative control, cells were incubated
with irrelevant Ab at the same concentration. As positive control, cells
were incubated with cisplatin at a final concentration of 400 μM per
well. At the end, cells were harvested with cold PBS after three washes
in the same buffer. Apoptotic/necrotic cells were detected using the
ApoScreen Annexin V-FITC kit according to the manufacturer’s in-
structions (Southern Biotechnology, Birmingham, AL). All experi-
ments were conducted in triplicate. A representative picture is shown.
Cytofluorometric Analyses of Propidium Iodide Staining
The HL-60 cells were plated at 2 × 105/well in a six-well plate and
incubated with CDR peptides at different concentrations for 12 hours
or a fixed concentration (0.5 mM) and variable periods at 37°C. Cyto-
fluorometric analyses of propidium iodide staining were performed ac-
cording to Nicoletti et al. [43]. Briefly, both detached and attached
cells were collected and incubated in a hypotonic fluorochrome solu-
tion (propidium iodide 50 μg/ml in 0.1% sodium citrate plus 0.1%
Triton X-100). The propidium iodide fluorescence of each sample was
analyzed by flow cytometry (BD, Franklin Lakes, NJ). Alternatively,
HL-60 transgenic variants overexpressing antiapoptotic molecules such
as Bcr-Abl, Bcl-2, and Bcl-XL were treated with CDR peptides at
0.5 mM for 12 hours and analyzed as described above. Each sample
was carried out in triplicates. Five individual experiments were analyzed.
In Vitro Angiogenesis Assay on Matrigel
The assay was prepared as previously described [44]. Briefly, BD
Matrigel Matrix (BD Biosciences) was distributed in 96-well plates
and allowed to polymerize for 1 hour at 37°C. The HUVEC cells
(5 × 103 cells/well) were suspended in 100 μl of RPMI medium sup-
plemented with 0.2% of fetal calf serum in addition to the synthetic
CDR peptides. The samples were added to each well and allowed to
grow at 37°C for 18 hours. Images were captured at 8× magnification
with a Sony (New York, NY) Cyber-shot camera coupled to a light
inverted microscope. The number of proangiogenic structures (closed
rings formed by intercellular projections) was counted from four dif-
ferent wells, and the average value was determined for each sample. As
a control of the assay, HUVEC cells were plated on Matrigel without
peptide addition.
Chemiluminescent-ELISA
CL-ELISA was carried out as previously described [37]. Briefly,
B16F10-Nex2 cells (104 cells/well) were fixed with 0.5% glutaral-
dehyde for 12 hours at 4°C in a white opaque ELISA plate (Nunc,
Roskilde, Denmark). After blocking with 1% BSA in PBS, 0.05%
Tween 20 (BPT), purified mAbs A4 and A4M were incubated for
12 hours at 4°C. Biotinylated antimouse IgG or IgM (Sigma) and
streptavidin-peroxidase (Sigma) were added at a dilution of 1:1000
in carbonate/bicarbonate buffer, pH 9.6, after incubating at 37°C for
30 minutes with gentle shaking. After several washes in BPT buffer,
the reaction was detected by enhanced chemiluminescence using the
ECL detection system following the manufacturer’s instructions (GE
Figure 1. Reactivity of mAb A4 and mAb A4M with B16F10-Nex2
tumor cells. (A) mAb binding to melanoma cells evaluated in CL-
ELISA. (B) Immunofluorescence of B16F10-Nex2 cells with mAb
A4 and mAb A4M. Negative control, melanoma cells incubated
with anti-Ig FITC alone.
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Healthcare Lifesciences, Piscataway, NJ). The chemiluminescence
readings were obtained in a microplate luminometer (Cambridge
Technology, Watertown, MA) and expressed as relative luminescent
units. Alternatively, for the binding competition assay, synthetic CDR
peptides were previously incubated at different concentrations with
B16F10-Nex2–coated plates for 12 hours at 4°C. After several washes
in BPT buffer, mAb A4 or A4M was added in triplicates at 10 μg/ml
per well and further incubated for 12 hours at 4°C. The reaction was
developed as described above.
Flow Cytometry (FACS)
B16F10-Nex2 cells (106/Eppendorf tube) were incubated with per-
meabilization buffer (PBS, pH 7.2, 0.5% saponin, 1% paraformal-
dehyde) for 20 minutes at 4°C. After several washes in PBS–saponin
0.5% (PBSs), CDR cyclic peptides (VH cCDR3) derived from both
mAb A4 and mAb A4M were added at three different concentrations
(50, 10, and 1 μg per sample) for 1 hour at 4°C. After three washes in
PBSs followed by blocking (1% BSA, PBSs), each sample was incu-
bated with 10 μg/ml of the corresponding mAb for 1 hour at 4°C.
Addition of the secondary Ab and data analysis were done as previ-
ously described. As negative control, cells were incubated only with
the secondary Ab. For positive control, samples were treated with
mAbs without peptide addition.
Animals, Tumor Growth, and Metastasis
Inbred male 8-week-old C57BL/6 mice were purchased from Cen-
tro de Desenvolvimento de Modelos Experimentais at the Federal
University of São Paulo (UNIFESP). All animal experiments were ap-
proved by the Animal Experimental Ethics Committee of UNIFESP.
Subcutaneous tumors were produced by injecting 5 × 104 B16F10-
Nex2 cells (single-cell suspensions, >95% viability by Trypan blue ex-
clusion test) in 0.1 ml of serum-free RPMI medium into the right
flank of each mouse (five animals per group). Five days after challenge,
the experimental group was treated intraperitoneally (i.p.) with mAb
A4 (500 μg per mouse) and subsequent 100-μg doses after 7 days
for 3 weeks. Tumor growth was recorded three times weekly with a
caliper, and the survival of challenged animals was scored and statis-
tically analyzed. The tumor volume was calculated using the formula:
V = 0.52 × D1
2 × D3, where D1 and D3 are the short and long tu-
mor diameters, respectively. Maximal volumes of 3 cm3 were allowed
Figure 2. MAb A4 is cytotoxic in melanoma cell lines. (A) Inhibitory mAb A4 effect against human melanoma cell lines in the absence of
complement. Cell viability was measured by MTT. Data are shown as mean percentage variation of cell death normalized to control. Con-
trol, cells incubated with an irrelevant antibody at 20 μg/well; *P< .001. (B) MAb A4 induced DNA degradation in B16F10-Nex2 and human
melanoma cell lines. STD, 1 Kb Plus DNA Ladder; Ctrl, cells incubated with irrelevant antibody at the same concentration. (C) B16F10-Nex2
cells were treated with mAb A4, cisplatin, or an irrelevant antibody as described in Materials and Methods for 6 and 12 hours. Increased
numbers of Annexin and propidium iodide (PI) double-positive cells were observed after mAb A4 and cisplatin incubation.
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before killing. For experimental lung metastasis assay, 5 × 105 tumor
cells, processed as described above, were injected into the tail veins
of mice (0.1 ml per mouse). Five days after challenge, the experi-
mental group was treated i.p. either with mAb A4 or with mAb
A4M (500 μg per mouse) followed by a single i.p. administration of
100 μg of mAb A4 or A4M after 7 days. Twenty days later, animals
were killed, their lungs were harvested, and the number of macro-
scopic surface tumor nodules was counted. Five mice were used in
each group. Administration of an irrelevant Ab of same isotype was
used as a negative control.
Statistical Analysis
Significant differences were assessed using Student’s t test. All ex-
periments were conducted two or more times. Reproducible results
were obtained, and representative data are shown. The survival plots
were analyzed by Kaplan-Meier log-rank test. In both tests, the dif-
ferences were considered statistically significant when P < .05.
Results
MAb A4 and mAb A4M React with B16F10-Nex2 Cells
MAb A4 (IgG2ak) was obtained as previously described by immu-
nization with whole B16F10-Nex4 cells grown in murine serum and
mixed with Alum [37]. Subcloning of the hybridoma disclosed a sec-
ond clone expressing mAb A4M (IgM). Both mAbs A4 and A4M
strongly reacted with B16F10-Nex2 cells in a dose-dependent man-
ner as shown by CL-ELISA (Figure 1A). Binding of mAb A4M was
less intense than that of mAb A4.
Immunofluorescence assay showed that mAb A4M reacted mainly
with nuclei of B16F10-Nex2 cells, whereas mAb A4 strongly reacted
Figure 3.MAb A4 recognizes protocadherin β13 on melanoma cells. (A) TL of B16F10-Nex2 was examined for reactivity with mAb A4. TL,
a band at 87 kDa was seen on SDS-PAGE; WB, a protein of identical molecular mass was recognized by mAb A4 in Western blot
analysis; IP, the 87-kDa component was immunoprecipitated by mAb. (B) A mAb A4-immunoprecipitated sample was analyzed by
LC–MS/MS, and the peptide shown underlined in bold italic and below was fully identified, being a characteristic of protocadherin
β13 (complete sequence shown, 796 aa, calculated mol. wt. = 87,458).
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with components on the cell surface and cytoplasm of tumor cells (Fig-
ure 1B). As previously shown, mAb A4 recognizes a mimetope of
melibiose. In contrast, binding of mAb A4M was not inhibited by
any carbohydrate tested (data not shown). Also, both Abs bound to
different peptides of a phage displayed a library of 9 to 12 aa peptides,
showing that they indeed have different specificities (data not shown).
MAb A4 Induces Apoptosis in Melanoma Cell Lines through
Binding to Protocadherin β13
We have shown that mAb A4 was cytotoxic to B16F10-Nex2 cells
in vitro, independent of complement. Cytotoxic assays were also run
without complement using three human melanoma cell lines
(SKmel25, SKmel28, and Mel85). MAb A4 significantly reduced
the cell viability of these cells by 50% at 15 μg/well compared with
nontreated cells (Figure 2A).
Interestingly, mAb A4 treatment in vitro led to substantial mor-
phological changes in tumor cells such as cell blebbing, shrinkage,
and loss of adherence. B16F10-Nex2, SKmel28, and Mel85 cells
were then incubated with mAb A4, and DNA fragmentation was
observed after 12 hours, suggesting the induction of apoptosis (Fig-
ure 2B). After treating with mAb A4 for 6 and 12 hours, adherent
and detached B16F10-Nex2 cells were harvested and further ana-
lyzed by flow cytometry for Annexin V binding and propidium io-
dide incorporation. As depicted in Figure 2C , cells treated with mAb
A4 for 12 hours had a twofold increase in double-positive cells com-
pared with the negative control (48% and 23%, respectively). Such
reactivity was similar to cisplatin treatment and showed that detached
melanoma cells rapidly evolved from an apoptotic to necrotic stage
incorporating propidium iodide.
To identify the mAb A4 ligand on melanoma cells, Western blot
analysis was carried out using B16F10-Nex2 total lysate. MAb A4 rec-
ognized a protein of 87 kDa as seen in Figure 3A (WB). The immuno-
precipitated sample with mAb A4 (Figure 3A, IP) was digested with
trypsin and analyzed by liquid chromatography–tandem mass spec-
trometry (LC–MS/MS). After removing the hits from a sample immuno-
precipitated by a control Ab and Ab sequences, we found only nine
Figure 4. MAb A4M reacts with histone 1 in B16F10-Nex2 cells. (A) Western blot analysis of B16F10-Nex2 nuclear extract (NE) and H1
commercially purified calf thymus histone (Sigma) with mAb A4M and anti–pan-histone antibody. Negative control, with irrelevant mAb.
(B) Confocal microscopy showing the mAb A4M reactivity on the nuclei of B16F10-Nex2 cells compared with antihistone antibody. Cells
untreated (Histone +) and treated with sulfuric acid to remove histones (Histone −) are compared. Bottom panel: Colocalization of mAb
A4M and antihistone reactions (MERGE). Red indicates phalloidin-rhodamine; blue, DAPI staining.
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candidates for the antigen recognized by mAb A4: cytochrome P450
2A5 (IPI: IPI00123964.1), elongation factor 1-α1 (IPI00307837.5),
elongation factor 1-α2 (IPI00119667.1), glycerol kinase-like protein 2
(IPI00123975.1),Golgi autoantigen (IPI00753818.1), L-lactatedehydro-
genase B chain (IPI00229510.4), LOC544907 protein (IPI00462354.1),
myeloid cysteine-rich protein (IPI00408687.1), and protocadherin β13
(IPI00129344.1; Figure 3B).
The latter was the only molecule that matched the antigen molec-
ular mass of 87 kDa recognized by mAb A4. A very well characterized
peptide, QYLQLDPQTQDLMLNENLDR, was found at 72 to 91
in the 796-aa protocadherin β13 glycoprotein. Murine and human
surface-expressed protocadherin-β one-exon gene families show a high
evolutionary conservation [45].
MAb A4M Recognizes Histone 1 in B16F10 Cells
MAb A4M strongly reacted with nuclei of B16F10-Nex2 cells,
which is consistent with its lack of cytotoxicity to whole tumor cells
in vitro with or without complement (not shown). Immunoblot anal-
ysis using B16F10-Nex2 nuclear extracts revealed that mAb A4M
recognized a single protein band at 32 kDa corresponding to histone 1
(Figure 4A). To confirm mAb A4M specificity, we compared its re-
activity with that of a commercial anti–histone 1 Ab. Both Abs reacted
with purified calf thymus histone (H1; Sigma). Antihistone reactivities of
both Abs were abolished after acid depletion of histones from B16F10-
Nex2 nuclei (Figure 4B). Moreover, mAb A4M colocalized to the nu-
cleus with antihistone Ab (Figure 4B, lower panel ).
MAbs A4 and A4M Inhibit Tumor Growth and Metastases
In Vivo
Mice challenged subcutaneously with B16F10-Nex2 cells were
treated with mAb A4. As depicted in Figure 5A, treatment with mAb
A4 rendered full protection against tumor growth (n = 5). All mAb-
treated animals were alive 40 days after challenge compared with none
in the untreated group (P < .001; Figure 5B). MAb A4M was inef-
fective in the same conditions (not shown). We then evaluated the
capacity of both A4 and A4MmAbs to inhibit metastases of melanoma
cells. Mice were injected intravenously with B16F10-Nex2 cells and
treated i.p. with mAbs A4 or A4M. A very significant reduction in
the number of lung metastases was seen with both mAbs (mean values:
A4 = 10, control = 150, P = .05; mAb A4M = 45, control = 155, P <
.05; Figure 5, C and D).
Figure 5. Antitumor effects ofmAbA4 andmAbA4M. (A)MAb A4 injected i.p. led to inhibition of B16F10-Nex2 subcutaneous tumor growth
(black circles, n = 5). Controls, animals injected i.p. with irrelevant antibody (white circles, n= 5). (B) Survival record of both groups treated
with mAb A4 and the control group (P< .001). (C) Effect of the mAb A4 andmAb A4M treatment on experimental lungmetastases showing
a significant decrease in their number with both mAbs (P = .05 and P < .05, respectively). (D) Representative lungs from control and mAb-
treated animals after 25 days of intravenous tumor challenge. Control, animals treated with irrelevant antibody at the same concentration.
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Synthetic Peptides On the Basis of the CDRs of mAb A4 and
mAb A4M Induce DNA Degradation and Inhibit Cell
Proliferation In Vitro
We have shown that synthetic CDR-related peptides derived from
Abs with different specificities could display antimicrobial, antiviral,
and antitumor effects in vitro and in vivo [36]. Presently, we exam-
ined the antitumor effects of CDRs from both mAbs A4 and A4M.
Synthetic peptides corresponding to the CDRs 1 to 3 of VL and 1
and 2 of VH were tested in the linear form after Kabat’s rules for their
localization and size. CDR3 of VH from both A4 and A4M were
tested in the linear configuration and in a cyclic-extended form
[46,47]. All sequences are shown in Table 1.
All CDRs from mAb A4 were screened in vitro against B16F10 cells.
Interestingly, only mAb A4 CDR H3 was cytotoxic to B16F10 cells,
Table 1. CDR Sequences of mAb A4 and mAb A4M.
CDR mAb A4 mAb A4M
H1 DFAMS EYTIH
H2 YISSAGSYIDYADTV WFYPGSGSIKYNEKF
H3 IRDGHYGSTSHWYF ARHEGRGWDYF
Cyclic H3 CIRDGHYGSTSHWYFDVWGC CARHEGRGWDYFDYWGC
L1 TATSSVSSSYLH RASGNIHNYLA
L2 STSNLAS NVKTLA
L3 HQYHRSPP QHFWSTPL
Italic: Cysteine added to obtain the cyclic peptide.
Underlined: Extended sequences as described by Morea et al. [48].
Figure 6. MAb A4 VH CDR3 (H3) peptide is the only inhibitory CDR of mAb A4 (A). A4 H3 peptide induces DNA degradation in B16F10-
Nex2 cells (B). STD, 1 Kb Plus DNA Ladder (Invitrogen). (C) Cyclic-extended and linear mAb A4 H3 peptides were tested for competition
with mAb A4 in CL-ELISA. Peptides were incubated with tumor cells previously to addition of mAb A4 as described in Materials and
Methods. (D) In vitro titration of cytotoxic effects of cyclic and linear mAb A4 H3 in B16F10-Nex2 cells. Black bar, untreated cells (*P <
.001). (E) Addition of cyclic-extended mAb A4 H3 peptide (50 μg) abrogates mAb A4 binding to B16F10-Nex2 cells (blue peak). Negative
control, cells incubated with anti-IgG FITC alone. Positive control, mAb A4 alone (red peak).
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inhibiting 50% of tumor cell growth at 0.06 mM (Figure 6A and
Table 2). Moreover, it led melanoma cells to apoptosis in vitro, induc-
ing DNA degradation (Figure 6B). The possibility that A4 CDR H3
might act as a micro-Ab with several functional characteristics of the
original mAb was initially tested in CL-ELISA. As seen in Figure 6C ,
the addition of the cyclic-extended form of A4 CDR H3 significantly
inhibited the mAb A4 binding to melanoma cells. The linear A4 CDR
H3 peptide was also inhibitory, but it was less active than the cyclic
peptide. Both cyclic and linear A4 CDR H3 peptides were cytotoxic
to B16F10-Nex2 cells, dramatically reducing the cell viability in a
dose-dependent manner (Figure 6D). In addition, FACS analyses re-
vealed that the cyclic A4 CDR H3 competed with mAb A4 for binding
to the same antigen on B16F10-Nex2 cells, with 100% inhibition of
mAb A4 binding at 50 μg of peptide (Figure 6E).
Likewise, CDR peptides derived from the mAb A4M were tested
against B16F10-Nex2 cells in vitro (Figure 7A). Two CDR peptides,
L1 and L2, were found to inhibit the tumor cell growth by 50% at
1.1 and 0.26 mM, respectively (Table 2). Alanine substitutions in the
A4M CDR L1 peptide at the C-terminus (tyrosine and leucine resi-
dues) revealed that this region is essential for the cytotoxic activity.
For the shorter A4M CDR L2 peptide, alanine substitutions of as-
paragine and mainly of threonine at positions 1 and 4 significantly
reduced the cytotoxic activity of the CDR (Table 2).
Further experiments showed that A4M CDR L1 and L2 induced
DNA degradation in B16F10-Nex2 cells (Figure 7B), suggesting that
these peptides could also trigger apoptosis in tumor cells. Additional
experiments using HL-60 leukemia cells and A4M CDR L2 revealed
typical apoptotic alterations including surface blebs and nuclear frag-
mentation (data not shown). Furthermore, the DNA degradation
was dose- and time-dependent (Figure 7C ). When HL-60 cells over-
expressing antiapoptotic molecules such as Bcr-Abl, Bcl-2, and Bcl-
XL were used, the L2 peptide cytotoxicity (DNA degradation) was
considerably inhibited (Figure 7C ).
Because angiogenesis is another important therapeutic target for
cancer treatment, we also tested A4M CDR peptides for the inhibi-
tion of endothelial cell (HUVEC) sprouting in Matrigel. The mAb
A4M CDRs L1 and L2 and, less intensely, H1 and L3 significantly
inhibited endothelial cell sprouting and intercellular connections in
the 60% to 90% range (P < .001; Figure 7D).
Although cytotoxicity against B16F10-Nex2 cells was observed
with L1 and L2 CDRs from mAb A4M, the Ab itself was not cyto-
toxic to whole tumor cells in vitro, indicating different mechanisms
of action and binding properties of these agents. The A4M CDR
H3 was not cytotoxic per se but was able to compete with mAb
A4M for binding to melanoma cells. The cyclic form of A4M CDR
H3 peptide inhibited mAb A4M binding to tumor cells as seen by
FACS (Figure 7E ) and by CL-ELISA where linear and cyclic forms
of mAb A4M H3 inhibited Ab binding (Figure 7F ). Thus, for mAbs
A4 and A4M, H3 CDRs played roles of micro-Abs, representing an
essential part of Ab-antigen recognition and, in some cases, displaying
similar functional activities.
Discussion
Antibodies directed to tumor-associated differentiation antigens may
have antitumor activities via CDC or ADCC as mediated by com-
plement or immune effector cells, respectively, for example, natural
killer and macrophages. These are not, however, the only mechanisms
of Ab antitumor cytotoxicity. MAbs may have a direct antitumor ac-
tivity without the participation of host components [48]. Abs do not
cross the plasma membrane, unless it is permeabilized, but may be
internalized by endocytosis. This may happen when the target is a re-
ceptor (e.g., receptors for transferrin, IL-2, EGF, TAPA-1 [the target of
an antiproliferative antibody]) [49–52], but internalization of a mAb
that recognized the Lewis Y carbohydrate epitope has also been reported
[53,54]. This Ab (BR96) in the absence of complement or effector cells
inhibited tumor cell DNA synthesis. However, it did not cause other
alterations typical of apoptosis. In comparison, antimelanoma mAb
A4 inhibited tumor cell growth in vitro in the absence of complement,
recognized a surface receptor identified as protocadherin β13 (Pcdh β13),
and was seemingly internalized, causing DNA degradation not only in
murine but also in human melanoma cells. Morphological changes
caused by mAb A4 such as cell blebbing, shrinkage, and loss of ad-
herence suggested the induction of apoptosis. Furthermore, mAb A4 ex-
erted a strong protective effect in vivo against B16F10-Nex2 melanoma
cells implanted subcutaneously or injected intravenously.
As Ab targets, protocadherins represent a large subgroup within
the cadherin family of cell-cell adhesion molecules. Many of the proto-
cadherins in mammals are expressed in the central nervous system with
a role in tissue morphogenesis, synaptic transmission, and specific con-
nections [55]. It is not surprising then that Pcdh β13 is expressed on
melanoma cells that originally derived from the neural crest. Pcdh pro-
teins may determine diverse neuronal connections that require tremen-
dous diversity for either positive or negative (detoxification) effects. A
tandem array of Pcdh variable exons, encoding distinct polypeptides,
participates in generating such diversity [56,57]. Invasive tumor cells
seem to have plasticity similar to multipotent embryonic progenitors
[58]. Recent evidence revealed that when melanoma cells were trans-
planted in the neural crest of chick embryo, the microenvironment had
the potential to control and reverse the metastatic phenotype. During
migration along the neural crest pathways, mouse melanoma cells
underwent apoptosis, which was assessed by anti–caspase 3 andTUNEL
staining [59]. We hypothesize that Pcdh β13 might be a regulatory sur-
face antigen of melanoma cells that, as shown in the present work, re-
sponded to mAb A4 binding leading cells to apoptosis. The binding
Table 2. In Vitro Antitumor Activity of Synthetic mAb A4 CDR H3 and of mAb A4M CDRs L1
and L2 and Their Alanine-Substituted Derivatives (asd ) against B16F10-Nex2 Melanoma Cells.
CDR EC50 (95% CI), M
A4 H3 6.00 (4.117-7.883) × 10−5
A4M L1 11.1 (10.222-11.978) × 10−4
A4M L2 26.1 (22.304-29.896) × 10−5
mAb A4M L1 asd EC50 (95% CI), M EC50asd/EC50L1
L1 R1A 12.2 (11.327-13.073) × 10−4 1.09
L1 S3A 12.2 (10.041-14.359) × 10−4 1.09
L1 G4A 13.5 (12.182-14.808) × 10−4 1.21
L1 N5A 10.8 (9.923-11.677) × 10−4 0.97
L1 I6A 13.5 (11.743-15.257) × 10−4 1.21
L1 H7A 11.5 (10.622-12.378) × 10−4 1.03
L1 N8A 11.1 (10.661-11.539) × 10−4 1.00
L1 Y9A 620 (616.08-623.92) × 10−4 55.85
L1 L10A 621 (619.57-620.43) × 10−4 55.94
mAb A4M L2 asd EC50 (95% CI), M EC50asd/EC50L2
L2 N1A 1388.0 (1378.0-1398.0) × 10−5 53.38
L2 V2A 41.6 (40.166-43.034) × 10−5 1.59
L2 K3A 163.0 (155.41-170.59) × 10−5 6.25
L2 T4A 2500.0 (2482.1-2517.9) × 10−5 95.78
L2 L5A 49.0 (37.525-60.475) × 10−5 1.87
CI indicates confidence interval.
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Figure 7.MAb A4M VL CDR1 and 2 (L1, L2) are cytotoxic to B16F10-Nex2 melanoma cells (A) and induce DNA degradation in these cells
(B). STD, 1 Kb Plus DNA Ladder. In human leukemia HL-60 cells, mAb A4M L2 peptide induces a dose- and time-dependent DNA deg-
radation, which is blocked in HL-60 cells overexpressing antiapoptotic molecules (*P < .001, **P < .01) (C). Inhibition by mAb A4M
CDRs L1 and L2 of HUVEC sprouting on Matrigel to form closed proangiogenic structures; *P < .001 relative to untreated control (−)
(D). The mAb A4M cyclic-extended H3 inhibited mAb A4M binding to B16F10-Nex2 as shown by FACS (E) and by CL-ELISA (F). Negative
control, cells incubated only with anti-IgM FITC. Positive control, mAb A4M alone (red).
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motif in the protocadherin shows a mimicry to the disaccharide meli-
biose as determined before, but the nature of the epitope, either linear
or conformational, is still unknown [37].
Whereas the obtainment of mAb A4 recognizing a minor compo-
nent in B16F10-Nex2 melanoma might be attributed to the immuni-
zation of mice with tumor cells grown in mouse serum–supplemented
medium, thus avoiding xenogeneic contamination, mAb A4M seemed
to respond as an autoimmune IgM reacting with nuclear histone H1.
Antihistone Abs have been detected in the sera of patients with various
autoimmune diseases and are predominantly directed to histone H1.
The preferential reactivity of mAb A4M with a nuclear component
was clearly shown in permeabilized tumor cells. Acid extraction of
histones abolished the reactivity of the Ab. Moreover, mAb A4M
did not react with DNA as tested in a Crithidia-DNA binding test
(not shown). In contrast to mAb A4, A4M was not cytotoxic in vitro.
If, however, the tumor cells had previously been permeabilized by a
membrane-interacting peptide (e.g., the antimicrobial gomesin),
mAb A4M showed additive cytotoxic activity [35].
MAb A4M also bound to intact melanoma cells in vitro with less
affinity compared with mAb A4. By examining a biotinylated surface
proteoma of B16F10-Nex2 melanoma cells kept for 24 hours in a fetal
calf serum–free medium, evidence was obtained for the presence of his-
tone H2B and histone H1.2 (unpublished data). It cannot be ruled out,
however, that mAb A4M surface reactivity might also involve a confor-
mational antigen mimicry. It has been reported that a mAb to Lewis Y/
Lewis b carbohydrate epitopes also bound to bovine histone H1 and
human histone H1.2 in a concentration-dependent manner [60]. His-
tone H2B was also recognized by the lung cancer–specific human mAb
HB4C5 [61]. Furthermore, anti-DNA auto-Abs were found to cross-
react with cell surface proteins from different cell types [62]. Then, it
seems that autoimmune antinuclear Abs have a potential to cross-react
with many other antigens of completely different structures.
Surprisingly, mAb A4M was protective in vivo against lung coloni-
zation by melanoma cells similarly to mAb A4. Antitumor activity was
not mediated by complement, as it was the case with several polyclonal
IgM Abs with antitumor activity [63,64]. There is evidence showing
that some IgM molecules recognizing cell surface carbohydrates may
have a tumor-suppressive activity by a macrophage-dependent mech-
anism [65]. Yet, another protective mechanism could involve an inflam-
matory response enhanced by IgM reactivity with necrotic tumor cells.
IgM Abs that recognize internal antigens in necrotic metastatic mela-
noma cells can also be used as carriers of radioactive isotopes as shown
with antimelanin Abs, thus becoming a valuable tool for radioimmuno-
therapy [66,67]. Therefore, both mAbs A4 and A4M of the present
work represent promising tools for the immunotherapy for metastatic
melanoma as shown in preclinical evaluation studies.
Polonelli et al. [36] obtained experimental evidence supporting the
concept that peptides derived from internal sequences of immuno-
globulins could display, with high frequency, antimicrobial, antiviral,
and antitumor activities in vitro, ex vivo, and in vivo. This was based
on a series of previous contributions, recently reviewed byMagliani et al.
[72], which showed that Ig fragments, tested as synthetic peptides
derived from CDR domains and/or framework regions of immuno-
globulins, had broad antibiotic properties similar to precursors and
actual protective molecules of native immunity [68–73]. The bioactivity
of these peptides was generally independent of Ab specificity, although
it is well known that VH CDR3 (H3) may, in several instances, re-
produce Ab-specific binding to the antigen and display the same bio-
logical activity [74–76]. The peptide (H3) with such properties is
called a micro-Ab [47,77]. Presently, we extended these studies to mAbs
A4 and A4M, with the perspective of additional antitumor molecules
being unraveled.
Both mAbs A4 and A4M generated micro-Abs represented by
peptide sequences of VH CDR3 tested as linear peptides or as ex-
tended H3 sequences made cyclic by adding Cys at the C-terminal
and forming a Cys-Cys bond under oxidation conditions [46]. Linear
and cyclic H3 peptides competed with mAbs A4 and A4M for bind-
ing to B16F10-Nex2 cells. The cyclic H3 form of mAb A4 showed
greater affinity for melanoma cells than the linear H3 form. Both
linear and cyclic mAb A4 H3 peptides inhibited growth of tumor
cells, and the linear form caused DNA degradation, suggesting that
the H3 peptide as well as the mAb A4 induced apoptosis in B16F10-
Nex2 cells.
The only CDR frommAbA4with antitumor activity was VHCDR3.
In contrast, VH CDR3 from mAb A4M was not cytotoxic, thus acting
as mAb A4M in vitro. Conversely, VL CDR 1 and VLCDR 2 frommAb
A4M inhibited growth of B16F10-Nex2 cells in vitro and caused
DNA degradation in the tumor cells. CDR L2, studied in greater detail,
was shown to degrade DNA in a dose- and time-dependent manner,
and its apoptotic effect was inhibited by the antiapoptotic Bcr-Abl,
Bcl-2, and Bcl-XL molecules transfected in HL-60 cells [78]. The anti-
tumor effect of mAb A4M CDR L1 was significantly inhibited by re-
placing the last two hydrophobic residues at the C-terminal by alanine,
thus suggesting a hydrophobic interaction with the tumor cell mem-
brane. The shorter mAb A4M CDR L2 sequence lost its antitumor ef-
fect in vitro by alanine replacement of asparagine and lysine but mainly
of threonine on the fourth position, suggesting a specific interaction
with a surface receptor on the tumor cell. Remarkably, both mAb A4M
CDRs L1 and L2 inhibited angiogenesis of HUVEC, which could also
suggest that these peptides may be protective in vivo similarly as pep-
tide C7 H2 and HuA L1 studied before [36].
In the present work, therefore, we describe two new specificities for
antimelanoma mAbs showing that both mAbs A4 (IgG2a) and A4M
(IgM) are protective in vivo against invasive B16F10-Nex2 cells in a
model of lung metastasis. MAb A4 but not mAb A4M was cytotoxic
in vitro and protective in the subcutaneous model of tumor develop-
ment. An apoptotic micro-Ab was recognized in the VH CDR3 of
mAb A4, and two VL CDRs (L1 and L2) of mAb A4M induced apop-
tosis of melanoma cells and inhibited angiogenesis. They not only sup-
ported the concept of intrinsic bioactivity of Ig peptide sequences but
also emerged as promising agents for antitumor therapy along with the
tumor-suppressive mAbs.
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